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A B S T R A C T
Vitamin D plays a role in muscle function through genomic and non-genomic processes. The objective of this
RCT was to determine the effect of monthly supplemental vitamin D3 onmuscle function in 70+ years old adults.
Participants (n=379) were randomized to receive, 12,000 IU, 24,000 IU or 48,000 IU of vitamin D3 monthly for
12 months. Standardized Hand Grip Strength (GS) and Timed-Up and Go (TUG) were measured before and after
vitamin D3 supplementation. Fasting total plasma 25 hydroxyvitamin D (25OHD) and Parathyroid Hormone
(PTH) concentrations were measured by Liquid Chromatography Tandem Mass Spectrometry (LC-MSMS) and
immunoassay, respectively. Baseline plasma 25OHD concentrations were 41.3 (SD 19.9), 39.5 (SD 20.6), 38.9
(SD 19.7) nmol/L; GS values were 28.5 (SD 13.4), 28.8 (SD 13.0) and 28.1 (SD 12.1) kg and TUG test values were
10.8 (SD 2.5), 11.6 (SD 2.9) and 11.9 (SD 3.6) s for the 12,000 IU, 24,000 IU and 48,000 IU dose groups,
respectively. Baseline plasma 25OHD concentration< 25 nmol/L was associated with lower GS (P=0.003).
Post-interventional plasma 25OHD concentrations increased to 55.9 (SD 15.6), 64.6 (SD15.3) and 79.0 (SD 15.1)
nmol/L in the 12,000 IU, 24,000 IU and 48,000 IU dose groups, respectively and there was a significant dose-
related response in post-interventional plasma 25OHD concentration (p< 0.0001). Post-interventional GS va-
lues were 24.1 (SD 10.1), 26.2 (SD10.6) and 25.7 (SD 9.4) kg and TUG test values were 11.5 (SD 2.6), 12.0 (SD
3.7) and 11.9 (SD 3.2) s for 12,000 IU, 24,000 IU and 48,000 IU dose groups, respectively. The change (Δ) in GS
and TUG from pre to post-intervention was not different between treatment groups before and after the ad-
justment for confounders, suggesting no effect of the intervention. Plasma 25OHD concentration was not as-
sociated with GS and TUG test after supplementation. In conclusion, plasma 25OHD concentration< 25 nmol/L
was associated with lower GS at baseline. However, monthly vitamin D3 supplementation with 12,000 IU,
24,000 IU and 48,000 IU, for 12 months had no effect on muscle function in older adults aged 70+ years.
Trial Registration : EudraCT 2011-004890-10 and ISRCTN35648481.
1. Introduction
Loss of muscle mass and decreased muscle strength are features of
ageing, with an annual loss of muscle mass of 0.5–1.0% per year after 70
years of age [1] and a 10–15% decline in muscle strength per decade in
older people aged 70–79 years [2]. Decreased muscle mass and strength can
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result in sarcopenia, which is associated with poorer quality of life, loss of
independence and increased health care costs [3]. Assessment of Hand Grip
Strength (GS) and Timed-Up and Go (TUG) are the widely used methods to
test the muscle strength and identify the presence of sarcopenia [4].
Links between vitamin D status and muscle function have been re-
ported based on mechanistic in vitro studies [5], human observational
[6–11], longitudinal [12] and intervention studies [13,14]. Some ob-
servational [6,9,13] and longitudinal [12] studies have reported posi-
tive associations between serum 25-hydroxyvitamin D (25OHD) con-
centration and muscle function in older adults, whereas other studies
did not find an association [11]. These conflicting findings may be due
to the differences in the characteristics of the population and differ-
ences in the vitamin D status of the participants. Current evidence
suggests that vitamin D status is associated with reduced muscle
strength, function and physical performance in older adults (over 60
years of age) only when serum 25OHD concentration falls below
50 nmol/L [15]. The scientific advisory committee on nutrition (SACN)
recommended that serum 25OHD concentration should be at least
25 nmol/L all year round for optimal bone and muscle health [16].
The findings from vitamin D intervention studies are inconsistent,
reflecting the variation in characteristics of the study population (e.g.
age, gender, baseline vitamin D status), study design and nature of the
intervention (route, dose, frequency and form of vitamin D supple-
mentation). Some studies show the positive effect of vitamin D sup-
plementation on muscle function only in older adults whose baseline
serum 25OHD concentrations< 30 nmol/L [17] or< 50 nmol/L [15].
Since the plasma concentration and vitamin D supply required for
optimal muscle function in older adults are not well understood, we
undertook a secondary analysis of a 1-year dose-ranging randomised
vitamin D3 supplementation trial, to evaluate its effects on muscle
function [18].
2. Materials and methods
Vitamin D in older people (VDOP) study was a randomized double-blind
interventional trial in 379 male and female older adults aged 70 years or
older, living in the North-East of England (55 °N), which recruited from
November 2012 and May 2013. The primary aim of this study was to assess
the effect of monthly dose of 12,000 IU, 24,000 IU or 48,000 IU (equivalent
to 400 IU, 800 IU or 1600 IU per day) vitamin D3 (Vigantol, Merck Sereno
GmbH, Darmstadt Germany) on bone mineral density [18].
Potential participants were identified through screening of the elec-
tronic records of 25 GP practices. Exclusion criteria comprised: taking
vitamin D supplements at a dose greater than 400 IU/day or calcium at a
dose greater than 500mg/day, a fragility fracture within the previous 6
months, treatment with an anti-resorptive or anabolic treatment for os-
teoporosis in the previous three years, a history of renal stones, previous
hip replacement or primary hyperparathyroidism, hypercalcaemia (al-
bumin adjusted plasma calcium>2.60mmol/L), hypocalcaemia (al-
bumin adjusted plasma calcium<2.15mmol/L) or an estimated glo-
merular filtration rate (eGFR) less than 30ml/min/1.73 m2). Ethical
permission was given by the Tyne and Wear Research Ethics Committee
(REC,12/NE/0050). All participants provided written informed consent.
The sponsor, Newcastle upon Tyne NHS Foundation Trust, provided the
Research and Development approval for the study (Trial registration:
EudraCT 2011 – 004890-10 and ISRCTN 35648481). Further details
about participant recruitment are published elsewhere [19].
2.1. Intervention and study visits
Participants were randomized to receive one of three doses of vi-
tamin D3, 12,000 IU, 24,000 IU or 48,000 IU, monthly for one year.
Both participants and investigators were blinded to the treatment re-
ceived. Study visits took place at baseline and thereafter at 3-monthly
intervals (5 in total). Participants were provided with 3-monthly sup-
plies of vitamin D3 at each study visit.
2.2. Outcome measures
GS (kg) in both the right and left hand was measured using a Jamar
hand-grip dynamometer (Jamar, Bollington, USA). Three measure-
ments were taken, and the mean value was used for analysis. The TUG
test was performed once and recorded as the time taken in seconds (s)
to stand from a sitting position in an arm chair and walk 3m distance
[20]. GS and TUG were measured before and after 1 year of supple-
mentation. Anthropometry, including, height, weight, Fat Mass (FM)
and Fat-Free Mass (FFM) were measured at three-month intervals.
Height was measured using a stadiometer and weight, FM and FFM
were measured using a bioelectrical impedance analyser (Tanita Crop,
Tokyo, Japan). Habitual dietary vitamin D intake was assessed using a
food frequency questionnaire (FFQ) at the screening visit, the 3rd and
5th visits. The vitamin D intake was calculated as the mean value of FFQ
data of screening visit, the 3rd and the 5th visits.
2.3. Biochemical analysis
Overnight fasting venous blood samples were collected from parti-
cipants at each visit. The 25OHD2 and 25OHD3 concentrations in
plasma were measured by Liquid Chromatography Tandem Mass
Spectrometry (LC-MSMS), before and after the intervention. Total
25OHD concentration was calculated by summing 25OHD2 and
25OHD3 values. EDTA plasma was used for the analysis of PTH by
immunoassay (Immulite, Siemens Healthcare Diagnostics Ltd,
Camberley, UK). Quality assurance of 25OHD and PTH assay were
performed as the part of vitamin D Quality Assessment Scheme (http://
www.deqas.org/) and the National External Quality Assessment
Scheme (https://ukneqas.org.uk/). Inter assay variations were<10%
and<7% for 25OHD2 and 25OHD3, respectively.
2.4. Data and statistical analysis
Baseline data were available for 379 older adults, while 343 older
adults completed the intervention study. Thus, the total sample of 379
was used for the baseline data analysis, while the data from 343 older
adults were used to investigate the intervention effects after 12 months.
Older adults were sub-divided into two groups based on baseline
plasma 25OHD concentration< 25 nmol/L, which is the cut-off of
value of vitamin D used in the UK to indicate an increased risk of de-
ficiency [16] and plasma 25OHD concentration< 50 nmol/L, which is
the cut-off for vitamin D inadequacy used in North America [21], both
of which have recently been incorporated in to the National Osteo-
porosis guidelines in the UK [22]. Statistical analysis of the data was
conducted using SPSS for Windows version 13.0. Kolmogorov-Smirnov
test was used to evaluate the distribution of the variables and those that
were not normally distributed were log transformed prior to the ana-
lysis and were near normally distributed after the conversion. Primary
outcomes for the study were GS and TUG in response to supplementa-
tion with 12,000 IU, 24,000 IU and 48,000 IU vitamin D3 per month.
Baseline 25OHD, baseline muscle function variables, age, weight,
height, FM, FFM and vitamin D intake were predetermined as potential
confounders. Multinomial logistic regression analysis was used to in-
vestigate the association between muscle function at baseline and
plasma 25OHD concentration (based on whether plasma level was
above or below two cut-offs: 25 nmol/L and 50 nmol/L), adjusting for
confounders. The ANOVA test was used to test the effect of vitamin D
supplementation on muscle function, plasma 25OHD and PTH con-
centrations. ANCOVA was used to test for the effect of the treatment on
post-intervention variables after controlling for potential confounders
(age, weight, height, Fat Mass (FM), Fat Free Mass (FFM) and vitamin D
intake). The Bonferroni test was used for post hoc comparisons. Multiple
linear regression was used to test potential effect of plasma 25OHD
concentration on muscle function after supplementation. A P value<
0.05 was considered as significant.
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3. Results
Table 1 presents the participants’ characteristics at baseline, strati-
fied by vitamin D3 supplementation dose. Baseline values for the main
outcome measures, GS, TUG and plasma 25OHD concentration were
similar across the intervention groups as were mean values for the main
confounders including weight, height, BMI and age indicating that
randomization was successful. The initial characteristics of the baseline
sample (379 participants) and the sample of older adults who com-
pleted the intervention study (343 participants) were similar (data are
not shown).
Table 2 shows the multinomial logistic regression analysis of the
relationships between baseline plasma 25OHD concentration and
muscle function variables according to the cut-offs values of plasma
25OHD concentrations from SACN, 2016 (25 nmol/L) and North
American Institute of Medicien (IOM), 2011 (50 nmol/L). After ad-
justing for age, body weight, height, FM, FFM and vitamin D intake,
older adults who had plasma 25OHD concentration<25 nmol/L at
baseline were significantly (p=0.003) less likely to have GS above the
median compared with individuals with plasma 25OHD concentra-
tion>25 nmol/L. This relationship was evident for GS for both males
(p= 0.015) and females (p=0.050). When using the cut-off value of
50 nmol/L, there was no relationship between vitamin D status and
either GS or TUG for all participants and for both gender groups.
After one year of vitamin D supplementation, there were no dif-
ferences between treatment doses for post-intervention GS or TUG. In
addition, there were no significant changes in GS and TUG from base-
line between intervention arms, with and without adjustment for
baseline values, age, gender, weight, height, FM, FFM and vitamin D
intake. Further, subgroup analysis of those with a baseline 25OHD
concentration<50 and< 25 nmol/L, did not show any significant
differences between intervention arms in post-intervention GS and
TUG, or for change in GS and TUG. As expected, there were significant
differences between treatment arms in post-interventional plasma
25OHD and change in 25OHD concentration. This relation was the
same for the sub-group analysis in those with baseline plasma 25OHD
concentration<50 nmol/L and<25 nmol/L. After the supplementa-
tion, the mean change in plasma 25OHD concentration was 14.3 (SD
12.6), 25.3 (SD 18.0) and 40.9 (SD 19.8) nmol/L for the 12,000 IU,
24,000 IU and 48,000 IU dose group, respectively. There was no sig-
nificant difference between the groups in unadjusted PTH post-inter-
vention, although the decrease in PTH was significant larger at the
Table 1
Participants’ characteristics at baseline by the dose of vitamin D supplementation.
Characteristics 12,000 IU 24,000 IU 48,000 IU
n (%) Mean SD n (%) Mean SD n (%) Mean SD
Age (years) 126 74.6 4.0 125 75.0 4.2 128 75.4 4.4
Age (n, % >70 < 71.5) 33 (26.2) 31 (24.8) 33 (25.8)
Age (n,% > 71.5 < 74) 36 (28.6) 30 (24.6) 28 (21.9)
Age (n,% > 74 < 77) 29 (23.0) 33 (26.4) 29 (22.7)
Age (n,% > 77) 28 (22.2) 31 (24.8) 38 (29.7)
Gender (n, % males) 126 (54.8) 125 (52.8) 128 (49.2)
Weight (kg) 126 73.9 11.8 125 77.1 14.0 128 76.1 14.2
Height (cm) 126 167.4 8.1 125 167.0 9.8 128 167.4 10.0
Waist (cm) 125 94.5 11.4 125 97.7 14.0 127 97.5 14.3
Hip (cm) 125 103.9 8.2 125 105.8 9.5 127 105.3 10.5
BMI1 (kgm−2) 126 26.3 3.6 124 27.5 4.1 127 27.2 4.0
< 18.5 0 (0.0)
50 (41.0)
60 (32.3)
16 (33.2)
1 (0.8)
31 (25.4)
65 (34.9)
28 (33.0)
0 (0.0)
41 (33.6)
61(32.8)
26 (33.8)
18.5 – 24.9
25.0 – 29.9
> 30.0
Body fat % 124 31.9 8.6 125 32.9 7.7 127 32.5 7.8
GS2 (kg) 126 28.5 13.4 124 28.8 13.0 127 28.1 12.1
TUG3 (s) 125 10.8 2.5 124 11.6 2.9 127 11.9 3.6
Plasma 25OHD4 (nmol/L) 126 41.3 19.9 124 39.5 20.6 128 38.9 19.7
PTH5 (Pg/ml) 126 48.6 25.7 123 47.4 23.3 128 49.9 21.3
Dietary vitamin D intake (μg/day) 119 3.6 2.0 121 3.6 2.5 123 4.0 3.0
1Body Mass Index 2 Grip Strength 3 Timed-Up and-Go4 25-hydroxy vitamin D 5Parathyroid Hormone.
Table 2
Multinomial logistic regression analysis1 of relationships between plasma 25OHD concentration, categorized according to SACN and IOM cut-offs, and muscle
function at baseline.
Total population (n= 379) Males (n= 198) Females (n= 181)
Classification OR CI P value* OR CI p value** OR CI P value**
GS (kg)
25OHD < 25 nmol/L2 0.339 0.166 – 0.691 0.003 0.333 0.137 – 0.810 0.015 0.251 0.063 – 1.001 0.050
25OHD >25 nmol/L Reference Reference Reference
25OHD < 50 nmol/L3 0.990 0.510 – 1.922 0.976 0.588 0.216 – 1.443 0.229 1.870 0.520 – 6.719 0.338
25OHD >50 nmol/L Reference Reference Reference
TUG (s)
25OHD < 25 nmol/L 0.645 0.388 – 1.070 0.090 0.501 0.229 – 1.093 0.084 0.720 0.358 – 1.446 0.355
25OHD >25 nmol/L Reference Reference Reference
25OHD < 50 nmol/L 0.697 0.424 – 1.147 0.155 0.775 0.386 – 1.543 0.468 0.584 0.273 – 1.250 0.166
25OHD > 50 nmol/L Reference Reference Reference
1To be in the category of higher muscle function based on dichotomisation at the median value 2 SACN cut-off 3IOM cut-off.
* Adjusted for gender, age, body weight, height, fat mass (FM), fat free mass (FFM) and dietary vitamin D intake.
** Adjusted for age, body weight, height, FM, FFM and dietary vitamin D intake.
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highest dose after correction for confounders. In subgroup analyses,
change in PTH was significantly different between intervention arms
before and after adjusting for confounders comparing those with
baseline 25OHD concentrations equal to or above with those below
50 nmol/L at baseline but this was not the case for the 25 nmol/L cut
point (Table 3).
After supplementation, plasma 25OHD concentration was not sig-
nificantly associated with either GS or TUG. Significant determinants
for GS after supplementation were height (p < 0.0001), gender
(p=<0.0001), age (p=0.002), concurrent body weight (p=0.040)
and FM (p=0.040). Similarly, the determinants of TUG were age
(p < 0.0001), height (p < 0.0001), fat mass (p=<0.0001), gender
(p=0.018) and vitamin D intake (p=0.019) (data are not shown).
4. Discussion
4.1. Main findings
This double-blind, randomized controlled study found that monthly
vitamin D3 supplementation with 12,000 IU, 24,000 IU and 48,000 IU
(which corresponds to 400, 600 and 1200 μg of dietary vitamin D per
day) for one year produced significant dose-related increases in plasma
25OHD concentration but had no effect on muscle function in older
adults. However, at baseline, there was an association between plasma
25OHD concentration and GS, with significantly lower GS for those
with baseline plasma 25OHD concentration< 25 nmol/L in both males
and females. After supplementation, there were no associations
Table 3
Effect of vitamin D supplementation on post-interventional and change (Δ) in muscle function variables, plasma 25OHD concentration and PTH concentration by the
dose of vitamin D supplementation.
Parameters 12,000 IU/month 24,000 IU/month 48,000 IU/month p1 p2
Total sample (n= 343)
Plasma 25OHD3 (nmol/L) (n=113) (n=114) (n=116)
Pre-intervention 41.2 (20.3) 39.4 (20.8) 38.5 (19.4) 0.495
Post-intervention 55.9 (15.6) 64.6 (15.3) 79.0 (15.1)* < 0.0001 <0.0001
Change (Δ) in 25OHD 14.3 (12.6) 25.3 (18.0) 40.9 (19.8)* < 0.0001 <0.0001
PTH4 (pg/mL)
Pre-intervention 46.8 (23.5) 47.1 (23.9) 50.6 (21.6) 0.443
Post-intervention 44.0 (21.3) 44.6 (24.5) 40.1 (18.4) 0.244 0.016
Change (Δ) in PTH −2.9 (18.4) −3.1 (18.2) −10.6 (15.4)* < 0.0001 0.001
GS5 (kg)
Pre-intervention 27.5 (12.7) 29.4 (13.2) 28.1 (12.2) 0.641
Post-intervention 24.7 (10.1) 26.2 (10.6) 25.7 (9.4) 0.692 0.449
Change (Δ) in GS −2.8 (11.6) −3.2 (8.1) −2.4 (7.7) 0.820 0.426
TUG6 (s)
Pre-intervention 10.9 (2.5) 11.5 (2.9) 11.8 (3.5) 0.187
Post-intervention 11.5 (2.6) 12.0 (3.7) 11.9 (3.2) 0.437 0.713
Change (Δ) in TUG 0.56 (2.32) 0.46 (2.77) 0.15 (2.5) 0.773 0.680
Older adults with baseline 25OHD < 50 nmol/L (n=242)
Plasma 25OHD (nmol/L) (n=75) (n=83) (n=84)
Pre-intervention 30.2 (10.9) 29.1 (10.3) 29.6 (10.6) 0.862
Post-intervention 49.7 (11.8) 60.5 (14.8) 76.8 (14.3)* < 0.0001 <0.0001
Change (Δ) in 25OHD 19.3 (10.0) 31.3 (15.0) 47.4 (15.3)* < 0.0001 <0.0001
PTH (pg/mL)
Pre-intervention 49.9 (24.9) 52.9 (24.4) 54.2 (22.0) 0.210
Post-intervention 45.7 (21.5) 48.9 (24.5) 41.0 (19.7) 0.137 0.101
Change (Δ) in PTH −4.2 (21.1) −4.0 (19.5) −13.4 (15.3)* 0.001 0.002
GS (kg)
Pre-intervention 26.5 (11.8) 29.1 (13.6) 28.3 (12.8) 0.457
Post-intervention 23.8 (10.3) 25.5 (10.3) 25.1 (9.3) 0.801 0.403
Change (Δ) in GS −2.7 (12.5) −3.6 (8.5) −3.1 (8.4) 0.486 0.889
TUG (s)
Pre-intervention 10.9 (2.3) 11.8 (2.9) 11.8 (3.2) 0.094
Post-intervention 11.7 (2.8) 12.3 (3.9) 12.0 (3.5) 0.560 0.630
Change (Δ) in TUG 0.74 (2.4) 0.45 (2.8) 0.29 (2.3) 0.512 0.823
Older adults with baseline 25OHD < 25 nmol/L (n=93)
Plasma 25OHD (nmol/L) (n=31) (n=30) (n=32)
Pre-intervention 19.3 (4.1) 18.2 (4.5) 18.8 (3.9) 0.582
Post-intervention 41.9 (10.7) 55.5 (14.7) 73.7 (12.8)* < 0.0001 <0.0001
Change (Δ) in 25OHD 22.6 (9.3) 37.3 (14.0) 54.9 (12.7)* < 0.0001 <0.0001
PTH (pg/mL)
Pre-intervention 61.9 (27.8) 59.5 (19.3) 58.8 (23.2) 0.930
Post-intervention 50.4 (20.6) 47.7 (16.6) 41.5 (24.1) 0.102 0.143
Change (Δ) in PTH −12.2 (25.9) −11.9 (17.4) −17.4 (14.7) 0.470 0.563
GS (kg)
Pre-intervention 25.6 (13.8) 24.1 (9.1) 25.8 (14.2) 0.895
Post-intervention 22.3 (11.2) 22.5 (9.0) 22.8 (7.9) 0.903 0.860
Change (Δ) in GS −3.3 (16.1) −1.6 (4.8) −3.0 (9.1) 0.814 0.714
TUG (s)
Pre-intervention 11.0 (2.4) 12.8 (3.7) 12.5 (4.1) 0.938
Post-intervention 11.9 (2.8) 13.7 (4.1) 12.9 (4.1) 0.798 0.379
Change (Δ) in TUG 0.91 (2.6) 0.88 (2.7) 0.38 (2.5) 0.806 0.823
1One-way ANOVA followed by Bonferroni test.
2ANCOVA controlled for baseline values of the variables, age, gender, weight, height, Fat Mass (FM), Fat Free Mass (FFM) and vitamin D intake.
325-hydroxyvitamin D 4 Parathyroid Hormone5Grip Strength 6Timed-Up and Go test.
* Significantly different from 12,000 IU and 24,000 IU groups.
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between plasma 25OHD concentration and muscle function. To our
knowledge, this is the first dose-ranging RCT conducted in the UK, with
a large number of free-living older adults, evaluating the effect of vi-
tamin D supplementation on muscle function.
4.2. Comparison with other studies
In line with our findings, previous RCTs reported that vitamin D
supplementation had no beneficial effect on muscle function in older
adults, irrespective of the dose of vitamin D supplements given. A re-
cent study of female adults of long-term care residence aged 65+ years,
supplemented with the oral dose of 800 IU vitamin D3 daily for 24
months, reported no effect of the supplementation on muscle function
measured by gait speed and physical performance test [23]. Another
study that conducted recruiting home-dwelling men and women
aged>70 years who were randomized to receive one of the oral doses
of 24,000 IU, 60,000 IU or 24,000 IU vitamin D3 with 300 μg of cal-
cifediol monthly for 12 months, reported no improvement in lower
extremity function measured by short physical performance battery
[24]. Hansen et al., 2015 reported that among postmenopausal women
aged 75 years or younger with baseline 25OHD concentration
14–27 ng/mL, (˜35–67.5 nmol/L) and supplemented with an oral dose
of 800 IU or 50,000 IU vitamin D3 twice monthly for one year had no
effect on muscle function, assessed by the ‘five sit-stand’ test and TUG
test [25]. Further, a recent systematic review of community-dwelling
older adults aged 65+ years showed that bolus injection or oral vitamin
D supplementation of dose ranging from 1000 IU – 600,000 IU, given
daily or weekly for duration ranging from 16 weeks to 20 months, had
no effect on GS and TUG test [26].
In contrast, some RCTs have shown improvements in muscle func-
tion following vitamin D supplementation in older adults. A study
conducted among residents of nursing homes of average age of 89
years, who had been randomized to receive one of four oral dose of
vitamin D3 supplements (200 IU, 400 IU, 600 IU and 800 IU) or placebo
daily for 5 months, showed that those receiving the highest dose had
the lowest number of falls compared to the other groups [27]. Positive
effects of oral vitamin D3 supplements on GS and chair rise test were
reported in a study of postmenopausal women aged 50–65 years who
received 1000 IU of oral vitamin D3 daily for 9 months [28]. A study of
ambulatory older adults with the history of falls and serum 25OHD
< 12 μg/L (˜ 30 nmol/L) who received a single intramuscular injection
of 60,000 IU of ergocalciferol reported a beneficial effect on functional
performance, reaction time and balance but not on muscle strength
[29]. Another RCT of ambulatory older adults live in a nursing home
with a serum 25OHD concentration<30 ng/mL (˜ 75 nmol/L), rando-
mized to receive the oral or intramuscular injection of 600000 IU of
cholecalciferol for 12 weeks, demonstrated an improvement in muscle
strength assessed using quadriceps and physical performance battery
[30]. According to Zhu et al., 2010, among community-dwelling older
adults aged 70–90 years with serum 25OHD concentration<24 ng/ml
(˜ 60 nmol/L) supplemented with 1000 IU of vitamin D2 daily for
1 year, improved TUG test only among the older adults who were the
slowest and weakest at the baseline [31]. Similarly, a systematic review
with a meta-analysis reported that vitamin D supplementation had a
positive effect on muscle function in older adults whose baseline serum
25OHD concentration was<25 nmol/L [32]. These inconsistent find-
ings are likely attributed to differences in study design including cohort
characteristics, duration, dosage, formulations, route of vitamin D
supplementation and the functional outcomes measured.
To support our finding of an association between GS and plasma
25OHD concentration below 25 nmol/L at baseline, Wu et al., 2017,
reported that the serum 25OHD concentration of 29–33 nmol/L may
optimise musculoskeletal health in middle-aged women (36–57 years)
[33]. Similar to our study Grimaldi et al., 2013, also reported a positive
association between serum 25OHD concentration and GS, but not with
other tests of muscle function and suggested that this might be related
to anatomical site differences in the androgenic effect of vitamin D or to
differences in vitamin D receptor expression between upper and lower
body muscle and consequently muscle function [34].
GS loss in our study was much higher than the reported values in
previous studies. The annual loss of GS among the older people aged
65–75 years reported in previous studies ranged from 0.3 to 1.3 kg
[35–37]. Though the GS is the standard method to assess sarcopenia,
differences in the equipment and methods used in various studies may
have caused variation in the measurements, making it difficult to
compare between studies [38].
In this study we found that plasma 25OHD concentration<25
nmol/L was associated with a lower GS. This finding supports the re-
commendation of SACN, UK that for the protection of musculoskeletal
health, serum 25OHD concentration should not fall below 25 nmol/L
throughout the year [16]. The US Institute of Medicine (IOM) defines
the desired range of 25OHD as 30–50 nmol/L and ESFA (European Food
Safety Authority [39];) advises a target value of 50 nmol/L for the
general population. The US Endocrine Society advises a target range
of> 50 nmol/L for patient management who are at risk of vitamin D
deficiency [40]. In addition, Kotlarczyk et. al., 2017 suggested that at
least a concentration between 30–40 ng/ml (˜75–100 nmol/L) is re-
quired for older adults for optimum muscle function [23]. With regards
to vitamin D supplementation, the American Geriatrics Society [41] and
the Endocrine Society [40] recommend vitamin D supplementation of
600–1000 IU/day in older adults who are at risk of falling. A systematic
review of vitamin D supplementation trials also reported a daily dose of
700–1000 IU for physical performance and to prevent falls [42]. SACN,
2016 suggests that for the adults> 50 years, the beneficial effect of
vitamin D supplementation on muscle strength and function can be seen
among the adults at the mean baseline serum 25OHD concentrations
ranging between 25 and 66 nmol/L. In our study, none of the inter-
vention groups reached a mean post-intervention plasma 25OHD con-
centration above this range. Accordingly, it can be speculated that the
dosages used in this study may not have been high enough to reduce the
negative effects of the ageing process. The absence of a detectable effect
of supplementation in this study may also be attributed to the fact that
only 30% of our participants had a 25OHD < 25 nmol/l at baseline.
However, as a result of lack of a placebo group we did not have data on
“natural decline” of muscle function of this group, thus we could not
compare the effect of vitamin D supplementation with that in non-
supplemented individuals.
For tissues other than the kidney, total 25OHD may not fully reflect
its availability for local hydroxylation into 1,25(OH)2D, which is the
active metabolite of vitamin D. Although 1,25(OH)2D is responsible for
the biological action of vitamin D, its systemic concentration does not
reflect function at the target tissue level [43,44]. Many vitamin D target
tissues, including the muscle tissue, are known to express the
1,25(OH)2D-producing enzyme CYP27A1 for auto- and paracrine
functions. Some reports suggest that muscle tissue may be capable of
internalising vitamin D binding protein bound 25OHD, although it re-
mains to be determined whether this is a significant route of cellular
supply of 25OHD [8]. To date, no data are available to identify whether
free 25OHD provides a better prediction of muscle function compared
to total 25OHD.
4.3. Limitations, strengths and future studies
We used the lowest intervention dose (which corresponds to the
current UK dietary recommendation) as the reference group but did not
include a placebo group in our study design as directed by the ap-
proving authorities. As a result, we could not establish the effect of
three doses of vitamin D supplements compared to a placebo group.
Further, we only measured plasma 25OHD concentration at baseline
and after 1-year supplementation. These samples were collected early
winter to late spring, during which vitamin D status is lower than the
year-round average in non-supplemented individuals. Therefore, the
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vitamin D status of individuals at baseline and post-intervention may
have been misclassified as it may not have fully reflected the trajectory
of vitamin D status throughout the year. Further, this population was
not selected randomly from the community. They were invited on the
basis of screening of pre-specified criteria in their electronic health
record. Also, there may have been self-selection bias as those that ex-
pressed an interest to participate in the study may have been more
health conscious. In addition, the response to vitamin D supplementa-
tion and status may have been influenced by factors not measured in
this study, such as the distribution of type I and type II of muscle fibres,
genetic factors, habitual physical activity or exercise habits and hor-
monal factors.
This study had several strengths. Its large sample size and the
number of available measurements that could potentially influence
muscle force, i.e. those related to body composition and size. The use of
three different vitamin D doses corresponding to the UK Recommended
Nutrient Intake (RNI) [16], the US Recommended Dietary Allowances
(RDA) [21] and the value below the Tolerable Upper Intake Level
(TUIL) was a strength of this study. We considered the effect of vitamin
D supplementation, without an exercise intervention, on muscle. Few
trials have looked at the potential interaction between exercise and
vitamin D, although a recent systematic review presented evidence of
an additive effect of resistance exercise and vitamin D3 supplementa-
tion for the improvement of muscle strength in older adults, and we
would support suggestions that this is an important area for future re-
search [45].
5. Conclusions
At baseline, plasma 25OHD was associated with GS in both male
and females, but only below the cut-off level of 25 nmol/L. Vitamin D
supplementation significantly increased the plasma 25OHD concentra-
tion of older adults in all doses of supplementation. Vitamin D sup-
plementation with 12,000 IU, 24,000 IU and 48,000 IU for 12 months
had no effect on muscle function in adults older than 70 years.
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